Breast Cancer Clinical Trial

Clinical Trial Finder Breast Cancer Trials

Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors

See Locations Near You

Summary

This is a two-part study of a compound called PF-05212384 (also known as PKI-587). The purpose of part 1 is to identify the Maximum Tolerated Dose (MTD) of PF-05212384 using a Continual Reassessment Method (CRM). Part 1 will include subjects with any solid tumor. In Part 2 two cohorts will be enrolled. One cohort will assess safety, tolerability and preliminary efficacy in 20 subjects at the MTD and will include subjects with breast cancer, ovarian cancer, endometrial cancer, colorectal cancer renal cancer or glioblastoma (a type of brain tumor). The other cohort will include 5 to 15 subjects with any type of tumor who consent to provide tumor biopsies while participating in the study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Pathologic diagnosis of any solid tumor
Incurable cancer, with disease progression following at least 1 therapy with no further standard treatment available in the opinion of the investigator.
At least 1 evaluable lesion per RECIST criteria

Exclusion Criteria:

Clinically unstable primary or metastatic CNS tumors
Subjects with known diabetes
QTc interval greater than 470 ms.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

78

Study ID:

NCT00940498

Recruitment Status:

Completed

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 8 Locations for this study

See Locations Near You

Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Beth Israel Deaconess Medical Center
Boston Massachusetts, 02215, United States
Dana-Farber Cancer Insitute
Boston Massachusetts, 02215, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Memorial Sloan-Kettering Cancer Center
New York New York, 10022, United States
Memorial Sloan-Kettering Cancer Center
New York New York, 10065, United States
Sarah Cannon Research Institute, Tennessee Oncology, PLLC
Nashville Tennessee, 37203, United States
Hospital General Vall D'Hebron
Barcelona , 08035, Spain
King's College London
London England, SE1 9, United Kingdom
Load More

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

78

Study ID:

NCT00940498

Recruitment Status:

Completed

Sponsor:


Pfizer

How clear is this clinincal trial information?

Clinical Trial Resources

SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials for Breast Cancer
Have You Been Diagnosed With Late-Stage Breast Cancer? Know That You Have Treatment Options.
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider